logo
Share SHARE
FONT-SIZE Plus   Neg

Amylin Pharma, Lilly Say BYETTA Approved For Use With Basal Insulin In Europe

Amylin Pharmaceuticals, Inc. (AMLN) and Eli Lilly and Co. (LLY) said the European Commission has granted marketing authorization to BYETTA as an adjunctive therapy to basal insulin, with or without metformin and/or Actos, for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The company noted that patients in the pivotal study achieved better glycemic control overall and after meals.

"The marketing authorization for the use of BYETTA with basal insulin provides a new option for the many patients with type 2 diabetes who are not achieving treatment goals," said Christian Weyer, senior vice president, research and development, Amylin Pharmaceuticals. "In a clinical trial, patients using fixed-dose BYETTA with titrated basal insulin achieved better postprandial and overall glycemic control, without weight gain or an increased risk of hypoglycemia, compared to patients using titrated basal insulin without BYETTA."

The main study included in the EU marketing authorization submission package was a double-blind, 30-week clinical trial published in Annals of Internal Medicine.

Further, as part of the transition plan outside the U.S., Amylin will assume responsibility for exenatide product commercialization efforts on a market-by-market basis by the end of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Telecommunications firm Sprint has extended its Black Friday unlimited data offer for a limited time, the company said in a statement on Monday. When customers switch at least one line to Sprint and sign up for Unlimited Freedom with AutoPay, they get unlimited data, talk and text starting at just $20 per month/line for a family of five until January 31, 2018. Shares of Cerecor Inc. (CERC) plunged over 13% on Monday on disappointing top-line clinical results from its phase II clinical trial of CERC-501 for smoking cessation. A US accounting watchdog slapped $8 million fine on Deloitte's Brazil division for issuing false audits of US-traded Brazilian airline Gol Intelligent Airlines in 2010. The agency also said that the company then doctored papers to thwart an investigation. The Public Company Accounting Oversight Board or PCAOB also announced a $750 thousand settlement with Deloitte Mexico.
comments powered by Disqus
Follow RTT